Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Nat Med. 2008 Jan 27;14(2):194–198. doi: 10.1038/nm1709

Figure 1.

Figure 1

CEP antigen and CEP-specific antibody titers in immunized mice. (a) Drawing of CEP adducted to MSA. (b) SDS-PAGE gel (left) and western blot for CEP (right) showing the MSA (lane 1) and two preparations of the CEP-adducted MSA (lanes 2 and 3, respectively) used. The bolus of the MSA protein in lane 1 is between 66 and 97 kDa. Lanes 2 and 3 show a higher mass range after adduction with CEP. Molar ratios of CEP to MSA were 11:1 in lane 2 and 6.6:1 in lane 3. The western blot shows strong CEP immunoreactivity in lanes 2 and 3. Minor CEP immunoreactivity is present in lane 1 (between the brackets). MWM, molecular weight marker. (c) CEP-specific antibody titer at the end of the short-term protocol (3 months) in each of the six treatment groups. (d) CEP-specific antibody titer at the end of the long-term protocol (12–14 months) in mice immunized with CEP-MSA or the indicated control treatments. Paired comparisons between CEP-MSA and all other groups are indicated with P values. NS, not significant.